OGEN · Oragenics Inc
$0.53
+0.01 (+1.90%)
At close · Aug 26
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Considering our recurring losses, accumulated deficit, and negative cash flows, the report of our independent registered public accounting firm on our consolidated financial statements for the year ended December 31, 2025, included an explanatory paragraph raising substantial doubt about our ability to continue as a going concern. ... These factors raise substantial doubt regarding our ability to continue as a going concern. We plan to pursue additional financing to mitigate liquidity risk; however, substantial doubt about our ability to continue as a going concern remains unless and until we obtain sufficient capital to fund operations beyond the current planning horizon. ... Based on these factors, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.37M
Shares
4.51M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$37.65K
-71.4%
FY2023
Net Income
-$9.84M
+6.9%
FY2025
Gross Margin
60.68%
-6.1pp
FY2014
Operating Margin
-55519.89%
-44555.3pp
FY2023
Diluted EPS
-$4.56
+90.5%
FY2025
Operating Cash Flow
-$9.25M
-7.5%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $37.65K | $131.52K | $86.99K | — | — | — | $0 | $0 | $0 | $939.93K | $1.03M | $1.33M | $1.44M | $1.31M | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $369.6K | $343.35K | $878.46K | $713.63K | $911.79K | |
| — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $570.33K | $688.88K | $453.3K | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | 60.68% | 66.74% | 34.04% | — | — | |
| $3.42M | $2.39M | $4.11M | $15.49M | $10.07M | $10.59M | $22.11M | $12.12M | $5.97M | $3.54M | $4.75M | $8.73M | $3.07M | $9.36M | $7.86M | $2.45M | $2.01M | |
| $7.05M | $6.97M | $6.44M | $5.45M | $4.48M | $5.27M | $4.53M | $3.76M | $4.02M | $3.18M | $3.79M | $3.05M | — | — | — | — | — | |
| $3.91M | — | — | — | — | — | — | — | — | — | — | $3.54M | $3.32M | $7.54M | $5.02M | $5.63M | $6.29M | |
| — | — | — | $27.39K | $44.67K | $41.24K | $51.71K | $62.62K | $30.11K | $65.8K | $75.04K | $71.15K | $27.67K | $76.49K | $75.19K | $79.52K | $42.74K | |
| $10.47M | $9.36M | $10.56M | $20.94M | $14.55M | $15.86M | $26.64M | $15.88M | $9.99M | $6.72M | $8.54M | $11.78M | $6.39M | $16.9M | $12.89M | $8.08M | $8.3M | |
| -$10.47M | -$9.36M | -$10.56M | -$20.9M | -$14.42M | -$15.77M | -$26.64M | -$15.88M | -$9.99M | -$6.72M | -$8.54M | -$11.78M | -$5.82M | -$16.21M | -$12.43M | -$7.35M | -$7.9M | |
| — | — | — | -55519.89% | -10964.61% | -18130.32% | — | — | — | — | — | — | -618.82% | -1570.4% | -933.52% | -508.59% | -603.76% | |
| — | — | — | -$20.88M | -$14.38M | -$15.73M | -$26.59M | -$15.81M | -$9.96M | -$6.65M | -$8.47M | -$11.71M | -$5.79M | -$16.13M | -$12.36M | -$7.27M | -$7.86M | |
| $18.63K | $785.93K | $29.83K | $30.59K | $15.1K | $15.76K | $10.69K | $7300 | $5786 | $216.33K | $4116 | $76.67K | $4030 | $17.54K | $655.56K | $332.35K | $33.86K | |
| $226.14K | $182.23K | $45.9K | $210.39K | $135.9K | $75.85K | $89.29K | $320.01K | $86.53K | $10.22K | $40.09K | $21.38K | $37K | $23.55K | $15.16K | $1044 | $3657 | |
| $181.21K | -$616.89K | -$9103 | $249.17K | $132.38K | $59.4K | $210.76K | $311.57K | $80K | -$13.21K | $45.19K | -$59.21K | $26.98K | $141.48K | -$658.15K | -$332.51K | -$635.93K | |
| — | -$9.98M | -$10.57M | -$20.66M | -$14.29M | -$15.71M | -$26.43M | -$15.57M | -$9.91M | -$6.73M | -$8.5M | -$11.84M | -$5.79M | -$16.07M | -$13.09M | -$7.68M | -$8.54M | |
| — | -$136.91K | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | $0 | — | — | -$733.44K | |
| -$1.23M | -$9.84M | -$10.57M | -$20.66M | -$14.29M | -$15.71M | -$26.43M | -$15.57M | -$9.91M | -$6.73M | -$7.01M | -$11.71M | -$5.79M | -$16.07M | -$13.09M | -$7.68M | -$7.81M | |
| — | — | — | -54858.14% | -10863.96% | -18062.03% | — | — | — | — | — | — | -615.95% | -1556.7% | -982.94% | -531.61% | -596.31% | |
| — | — | — | — | — | — | — | -$15.57M | -$11.33M | -$6.73M | — | — | — | — | — | — | — | |
| USD/shares | $1.11 | -$4.56 | -$47.88 | -$275.40 | -$213.30 | -$242.70 | -$846.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $1.11 | -$4.56 | -$47.88 | -$275.40 | -$213.30 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 2.16M | 220.73K | 74.99K | 66.97K | 64.77K | 31.41K | 23.49K | 7243.9572 | 2736.8194 | 2478.2961 | 20.36K | 20.09K | 15.99K | 9853.1983 | 3176.4072 | — |
| shares | — | 2.16M | 220.73K | 74.99K | 66.97K | 62.73K | 31.41K | 23.49K | 7243.9572 | 2736.8194 | 2478.2961 | 20.36K | 20.09K | 15.99K | 9853.1983 | 3176.4072 | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.62×
EV/EBIT
—
P/E (TTM)
—
Peer medians compare against the 126 similar-size Biotechnology companies (of 534 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2023 | FY2022 | FY2021 |
|---|---|---|---|
| Grant | $250,000 | $250,000 | $250,000 |
Key facts
CIK
1174940
CUSIP
684023609
13F (30d)
17 filings
15 filers
Visit website
Investor relations